GLP1R and medullary thyroid gland carcinoma: These findings are particularly intriguing given the FDA’s warnings about the potential increased risk of thyroid cancer, specifically medullary thyroid carcinoma, in patients treated with the GLP-1 receptor agonists [6, 7].